CTOs on the Move

10X Genomics

www.10xgenomics.com

 
10x Genomics meets the critical need for long range, structural and cellular information, with an innovative system that transforms short-read sequencing technologies. Our Chromium™ System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information at unprecedented scale, including phased structural variants, phased single nucleotide variants, and dynamic gene expression of individual cells—while leveraging their existing sequencing systems and workflows.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.10xgenomics.com
  • 7068 Koll Center Parkway Suite 401
    Pleasanton, CA USA 94566
  • Phone: 925.401.7300

Executives

Name Title Contact Details
Jason Gao
Head of Information Security Profile

Funding

10X Genomics raised $55M on 03/17/2016
10X Genomics raised $75M on 04/26/2018
10X Genomics raised $50M on 04/26/2018
10X Genomics raised $35M on 01/07/2019

Similar Companies

Columbus Children's Research Institute

Columbus Children's Research Institute is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FirstString Research Inc

FirstString Research was founded on a vision to deliver clinically relevant and effective solutions for the treatment of diseases based upon insights and understanding from the molecular and cellular contexts that define the underlying pathology.

Picometrics

Picometrics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arcutis

Arcutis was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team`s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis` combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.

Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for oral treatment of acute and chronic pain; and TRV250 is in preclinical development for the treatment of migraine. In addition, Trevena has an early stage portfolio of drug discovery programs currently in lead optimization.